Carregant...
Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study
Although immune-checkpoint inhibitors (ICIs) have become an important choice of treatment for advanced NSCLC, recent reports show hyperprogressive disease (HPD) after ICI administration. The clinico-pathological features of HPD still remain unclear. Here we report a 65-year-old man with lung adenoca...
Guardat en:
| Publicat a: | Respir Med Case Rep |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6586950/ https://ncbi.nlm.nih.gov/pubmed/31249779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2019.100885 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|